

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
	appear
Company	General
AstraZeneca (tezepelumab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Allergy UK	Board of Community Health Councils in
Anaphylaxis UK Asthma Llung LlK	Wales
Asthma + Lung UK Asthma Policif Charity	British National Formulary Care Quality Commission
Asthma Relief CharityNARA – The Breathing Charity	Care Quality CommissionDepartment of Health - Northern Ireland
Sinus UK	Healthcare Improvement Scotland
SmellTaste	 Medicines and Healthcare products
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	 National Association of Primary Care
The Samter's Society	National Pharmacy Association
,	NHS Confederation
Healthcare professional groups	NHS Wales Joint Commissioning
Association of Respiratory Nurse	Committee
Specialists	Scottish Medicines Consortium
Association for Respiratory Table 20 and Physicle 20	Welsh Government
Technology and Physiology	
Association of Surgeons of Great Britain and Ireland	Possible comparator companies
British Association of	 Sanofi (dupilumab)
Otolaryngologists, Head & Neck	carion (adpliantab)
Surgeons	Relevant research groups
British Geriatrics Society	Asthma, Allergy and Inflammation
British Society for Allergy and Clinical	Research Trust
Immunology	British Association for Lung Research
• ENT UK	Cochrane Airways Group
National Heart and Lung Institute	David Hide Asthma and Allergy
Primary Care Respiratory Society UK	Research Centre
Royal College of Anaesthetists Paral College of Company Prophition and College of Company Prophition and College of Company Prophition and College of College o	Genomics England MBC Clinical Trials Unit
Royal College of General Practitioners Royal College of Nursing	MRC Clinical Trials UnitNational Institute for Health Research
Royal College of NursingRoyal College of Pathologists	National Institute for Health Research
 Royal College of Pathologists Royal College of Physicians 	Associated Public Health groups
• Royal College of Fifysicialis	

Stakeholder list for the evaluation of tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

Issue date: December 2025



Consultees	Commentators (no right to submit or appeal)
 Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	Public Health WalesUK Health Security Agency
Others Department of Health and Social Care NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,

Stakeholder list for the evaluation of tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

Issue date: December 2025



the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.